Achieve Life Sciences

Contributing Author

Recent Articles by Achieve Life Sciences

May-05	Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 ACHV GlobeNewswire
Apr-16	Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors ACHV +35.49% GlobeNewswire
Apr-16	Achieve Life Sciences Announces Up to $354 Million Private Placement ACHV +35.49% GlobeNewswire
Apr-15	Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions ACHV GlobeNewswire
Mar-26	Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability ACHV GlobeNewswire
Mar-24	Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates ACHV -28.40% GlobeNewswire
Mar-17	Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026 ACHV GlobeNewswire
Mar-04	Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study ACHV +5.77% GlobeNewswire
Jan-30	Achieve Life Sciences Announced Granting of New Hire Inducement Awards ACHV GlobeNewswire
Jan-12	Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer ACHV GlobeNewswire
Dec-08	Achieve Life Sciences Announced Granting of New Hire Inducement Awards ACHV GlobeNewswire
Nov-06	Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program ACHV GlobeNewswire
Nov-03	Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation ACHV GlobeNewswire
Oct-29	Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025 ACHV GlobeNewswire
Oct-20	Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer ACHV +19.05% GlobeNewswire
Oct-17	Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation ACHV +36.36% GlobeNewswire
Oct-02	Achieve Life Sciences Announces Granting of New Hire Inducement Awards ACHV GlobeNewswire
Sep-22	Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD ACHV GlobeNewswire
Sep-18	Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer ACHV GlobeNewswire
Sep-11	Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer ACHV GlobeNewswire
Sep-03	Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation ACHV GlobeNewswire
Sep-02	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences ACHV GlobeNewswire
Aug-07	Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program ACHV GlobeNewswire
Jul-29	Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference ACHV -5.20% GlobeNewswire
Jul-24	Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025 ACHV GlobeNewswire
Jun-30	Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities ACHV GlobeNewswire
Jun-26	Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering ACHV -36.47% GlobeNewswire
Jun-26	Achieve Life Sciences Announces Proposed Underwritten Public Offering ACHV -36.47% ACHV -7.63% GlobeNewswire
Jun-26	Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades ACHV -36.47% ACHV -7.63% GlobeNewswire
Jun-26	Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation ACHV -36.47% ACHV -7.63% GlobeNewswire
May-28	Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference ACHV GlobeNewswire
May-20	Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake ACHV GlobeNewswire
May-13	Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program ACHV +6.85% GlobeNewswire
May-06	Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025 ACHV -6.25% GlobeNewswire

Achieve Life Sciences

Recent Articles by Achieve Life Sciences

Upgrade your Finviz experience